Literature DB >> 5576142

Good-bye, Mr. Gibbs.

J Elia.   

Abstract

Mesh：

Year:  1971        PMID： 5576142     DOI： 10.1056/nejm197105272842119

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  25 in total

Review 1.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.

Authors:  Jan Hrudka; Kateřina Lawrie; Petr Waldauf; Vanda Ciprová; Jana Moravcová; Radoslav Matěj
Journal:  Virchows Arch       Date:  2020-05-18       Impact factor: 4.064

Review 4.  Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer.

Authors:  Flavio G Rocha
Journal:  Ann Surg Oncol       Date:  2021-01-01       Impact factor: 5.344

5.  Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Authors:  Heinz Läubli; Stefan Dirnhofer; Alfred Zippelius
Journal:  Virchows Arch       Date:  2018-08-25       Impact factor: 4.064

Review 6.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

7.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

8.  High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.

Authors:  Elena Anghileri; Natalia Di Ianni; Rosina Paterra; Tiziana Langella; Junfei Zhao; Marica Eoli; Monica Patanè; Bianca Pollo; Valeria Cuccarini; Antonio Iavarone; Raul Rabadan; Gaetano Finocchiaro; Serena Pellegatta
Journal:  Cancer Immunol Immunother       Date:  2020-11-03       Impact factor: 6.968

Review 9.  A view on drug resistance in cancer.

Authors:  José Baselga; David M Hyman; Neil Vasan
Journal:  Nature       Date:  2019-11-13       Impact factor: 49.962

10.  Quantitative evaluation of MSI testing using NGS detects the imperceptible microsatellite changed caused by MSH6 deficiency.

Authors:  Gou Yamamoto; Takashi Takenoya; Akemi Takahashi; Yukiko Osanai; Miho Kakuta; Tetsuhiko Tachikawa; Takanori Washio; Masato Kamiyama; Michio Shiibashi; Shigeki Yamaguchi; Kiwamu Akagi
Journal:  Fam Cancer       Date:  2021-04       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.